Floatz logo

Busulphan

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Fujian Medical UniversityDormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
81/ 100

Competitive context

21 Active assets in the Precursor Cell Lymphoblastic Leukemia-Lymphoma cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
Institute of Hematology & Blood Diseases Hospital, China
Phase 2B
FILGRASTIM
Janssen Research & Development, LLC
Phase 2B
Cyclophosphamide
Institute of Hematology & Blood Diseases Hospital, China
Phase 2B
ETOPOSIDE
Asan Medical Center
Phase 2B
DARATUMUMAB
Janssen Research & Development, LLC
Phase 2B

View all 36 →

Same molecule, other indications

Busulphan is also rated in:

plasma cell myelomaDormant
BBB
Indicative ·
77 / 100
View asset →
myelodysplastic/myeloproliferative neoplasmDormant
BBB
Indicative ·
76 / 100
View asset →
graft versus host diseaseDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →